Ukraine’s prosecutor general seen as possible successor to President Poroshenko — MPWorld October 25, 0:23
51 ceasefire violations reported in Syria in past day — Russian reconciliation centerWorld October 24, 23:32
Two Ukrainian cities support initiative for broader status of Russian languageWorld October 24, 23:31
Russian Baltic Fleet’s training ship Smolny ends its visit to GreeceMilitary & Defense October 24, 21:23
Diplomat: US needs alleged attack on Russian ministry website to hype up cyberwar topicRussian Politics & Diplomacy October 24, 21:03
IOC confirms talks between Thomas Bach and Russia’s whistleblowing couple StepanovsSport October 24, 20:34
Scottish rockers Nazareth will record album with new vocalist in 2017Society & Culture October 24, 20:23
Lavrov, Kerry agree to continue consultations on Aleppo — ministryRussian Politics & Diplomacy October 24, 20:11
Russian diplomat does not rule out Ukraine may provoke another gas crisis with EURussian Politics & Diplomacy October 24, 19:50
NOVOSIBIRSK, June 4. /TASS/. Clinical tests of anti-Ebola vaccine developed by the Novosibirsk-based Vector state research centre of virology and biotechnology will begin in August, Valery Mikheyev, Vector’s acting director general, said on Thursday.
"We have several variants. Work is underway. Some of the variants are ready. We will soon submit them for clinical testing. One of the preparations is ready, two or three more will be ready soon," he told journalists on the sidelines of the 3rd international forum of technological development Technoprom-2015 being held in Novosibirsk on June 4-5.
He said his centre was supposed to yield vaccine variants in August. "We will chose the most efficient vaccine to launch into production," he added.
According to the World Health Organization (WHO), the death toll from the current Ebola outbreak has reached in West Africa exceeded 11,140 and the number of those infected was over 27,13o as of June 1.
The World Health Organization describes Ebola virus disease (formerly known as Ebola haemorrhagic fever) as "a severe, often fatal illness, with a case fatality rate of up to 90%." Symptoms include sudden onset of fever, intense weakness, muscle pain, headache and sore throat. This is followed by vomiting, diarrhoea, rash, impaired kidney and liver function, and in some cases, both internal and external bleeding. The infection is transmitted by direct contact with the blood, body fluids and tissues of infected animals or people. People are infectious as long as their blood and secretions contain the virus. The incubation period is 2 to 21 days. There is no known cure or vaccine for the disease. The only treatment offered is "supportive intensive care.".